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Objectives. This study sought to describe the economic out- 
comes from a prospective multicenter registry of primary corn- 
nary angioplasty. 
Background. Interest in coronary angioplasty without preced- 
ing thrombolytic therapy as a primary reperfusion strategy has 
increased as a result of three recent randomized trials showing 
outcomes equivalent to or better than standard thrombolytic 
therapy. 
Methods. The Primary Angioplasty Registry enrolled 270 pa- 
tients with acute myocardial infarction at six private tertiary care 
medical centers. Baseline and follow-up medical costs and counts 
of resources consumed were collected from enrollment o the 
6-month follow-up visit. Correlates and predictors of cost were 
identified with multivariable inear regression modeling. 
Results. Ninety-five percent of patients had a revascularization 
procedure during the baseline hospital period: 85% had coronary. 
angioplasty only; 4% had coronary bypass urge~ only; 6% had 
both procedures. The total mean baseline hospital cost (not 
charge) was $13,113, with mean physician fees of $5,694. During 
the follow-up eriod, repeat coronary angiography was performed 
in 21% of patients, whereas 13% had repeat angioplasty and 3% 
bypass urgery. Mean hospital follow-up costs were $3,174, with 
mean physician fees of $1,443. Independent correlates of higher 
baseline hospital costs included older age (p = 0.049), anterior 
infarction (p = 0.03), initial Killip class (p < 0.0001), more severe 
coronary disease (p = 0.0015), need for bypass urgery alone or in 
addition to angioplasty (p < 0.0001) and recurrent ischemia (p < 
0.0001). 
Conclusions. Costs of primary angioplasty for patients with 
acute myocardial infarction eligible for thrombolysis were 
strongly influenced by infarction- and procedure-related compli- 
cations but only modestly influenced by patient selection factors. 
(J Am Coll Cardiol 1995;26:688-95) 
Interest in the use of coronary angioplasty without preccding 
thrombolytic therapy as a primary reperfusion strategy in 
patients with acute myocardial infarction has increased sincc 
three recent randomized trials each reported more favorable 
outcomes with this form of therapy than with standard throm- 
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bolysis (1-5). Although none of these trials was large enough 
to detect mortality differences individually, the aggregated 
mortality results trongly favored primary angioplasty (4,6,7). 
All the centers participating in these trials were very experi- 
enced in the procedure. In light of these results, a large-scale 
trial is currently being conducted (Global Use of Strategies 
to Open Occluded Arteries in Acute Coronary Sydromes 
[GUSTO] II) to determine whether the benefits of primary 
angioplasty observed at these centers can be replicated at less 
experienced centers. Important concerns about a primary 
angioplasty reperfusion strategy include its general feasibility, 
because most reports to date have originated from investiga- 
tors who have been proponents of the technique, and its cost. 
With regard to the latter issue, two randomized trials have 
suggested that hospital charges may actually be higher with 
thrombolysis than with primary angioplasty (1,2). However, no 
large-scale study has described etailed medical resource use 
patterns and associated medical costs (not charges) (8,9) with 
primary angioplasty. 
The Primary Angioplasty Registry was initiated in 1990 to 
collect outcome data for a large multicenter series of patients 
(~'~lt)t)5 b,,the Amcric:u7 (~tlcgc ~q ('~ndioh,~x 0735-1097/95/$9.50 
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with acute myocardial infarction treated with this strategy (10). 
The registry included six clinical sites and a separate coordi- 
nating center that provided an independent review of clinical, 
angiographic, economic and quality of life outcomes. This 
report describes the economic outcomes from this registry. 
Methods  
Patients. The Primary Angioplasty Registry was a collabo- 
rative project involving six clinical sites plus the independent 
coordinating center (10). To allow comparison with published 
thrombolytic therapy trials, entry and exclusion criteria used 
for this registry were similar to those of previous U.S. throm- 
bolysis trials. These included a symptom duration window of 
20 min to 12 h and the requirement of ->1 mm of ST segment 
elevation in two contiguous leads on the qualifying electrocar- 
diogram. However, in contrast o many previous trials, no 
upper age limit was used. Exclusions included standard con- 
traindications to thrombolysis (10). Between July 1990 and 
February 1992, 271 patients met these criteria and were 
enrolled in the registry; for administrative r asons, one patient 
was excluded from the economic substudy, leaving a final 
group of 270. 
Overview of Primary Angioplasty Registry treatment strat- 
egy. The Primary Angioplasty Registry protocol has been 
previously described (10). In brief, in addition to standard 
acute myocardial infarction care, clinically eligible patients 
were taken emergently to the cardiac catheterization labora- 
tory for diagnostic angiography and, whenever technically 
feasible, primary coronary angioplasty. Patients with unsuit- 
able anatomy for angioplasty (10%) underwent emergency 
coronary bypass urgery or were treated medically. Thus, the 
outcomes from the Primary Angioplasty Registry are those of 
an intention-to-treat strategy rather than the results of a series 
of patients preselected because of their suitability for primary 
coronary angioplasty. Before initiation of the registry, each 
potential angioplasty operator was required to provide data 
about past experience (numbers, success rate, complication 
rate) with the procedure, and a random sample of five angio- 
plasty films from each investigator were reviewed by the 
angiographic core laboratory. All study data were prospectively 
collected by a coordinator at each site and were subsequently 
audited on-site by a nurse or monitor from the coordinating 
center. 
Postprocedural care was decided by each patient's attend- 
ing cardiologist, but investigators were encouraged tolimit the 
use of transfusions, repeat catheterization a d coronary bypass 
surgery (10). The only tests specifically required by the study 
protocol were a 6-week exercise-gated blood pool scan and a 
6-month repeat cardiac atheterization. 
Measurement of economic outcomes. Economic outcomes 
were assessed in terms of both medical costs and medical 
resource consumption (9,11). For each patient enrolled in the 
Primary Angioplasty Registry, we obtained copies of all hos- 
pital and physician bills covering the patient's medical care 
from the time of randomization through the 6-month follow-up 
point, at which the protocol terminated. Both itemized and 
summary ledger forms (UB 82) of hospital bills were obtained. 
Physician bills were collected from the patient's cardiologist(s) 
and (when relevant) cardiovascular surgeon. 
Hospital charges were converted to hospital costs using the 
cost/charge ratios and per diems derived from each hospital's 
annual Medicare Cost Report (9). The importance of this 
conversion has previously been discussed (8,9,11). Because 
there is no analogous conversion for physician fees, these were 
tabulated in their original form. Physician bills for outpatient 
follow-up care were not collected, although the type and 
amount of care received were collected in detail, and these 
data along with the Medicare fee schedule were used to 
estimate outpatient physician fees. The collection of cost data 
was terminated just before the 6-month protocol recatheter- 
ization. In addition to medical costs, counts were made of 
medical resources consumed uring the study, including "big- 
ticket" inpatient care items (such as coronary care unit and 
total hospital length of stay, cardiac atheterization a d revas- 
cularization procedures), follow-up hospital admissions, and 
outpatient medical visits. Follow-up medical care data were 
obtained by patient interview at the time of the 6-month 
follow-up contact. 
Data analysis. Descriptive statistics are presented as per- 
cents for discrete variables and medians and interquartile 
ranges (25th to 75th percentiles) or mean values and standard 
deviations for continuous variables. Because of the substantial 
skew that cost data tend to display, they present aproblem for 
descriptive statistics. Thus, we present both mean values 
(reflecting the best estimate of the cost of the program 
expressed on a per-patient basis) and medians (best reflection 
of the cost of the "typical" patient). For graphic presentation 
of cost subgroups, we used Kaplan-Meier curves (12,13) that 
show the proportion of the cohort or of subgroups at different 
levels of total cost. Multivariable analysis of cost predictors and 
cost correlates was performed with a multivariable linear 
regression model after log transformation f the dependent 
variable (hospital cost). 
Resu l ts  
The baseline characteristics, acute catheterization results 
and hospital outcomes from the Primary Angioplasty Registry 
have been reported previously (10) and are summarized in 
Table 1. Entry and exclusion criteria, designed to mimic a 
thrombolysis trial, resulted in a patient cohort with a median 
age of 59, 74% men and 42% with an anterior myocardial 
infarction. The median time from symptom onset o angiogra- 
phy was 3.2 h; all patients had an acute angiogram, and primary 
angioplasty of the infarct artery was attempted in 90%. The 
hospital mortality rate was 4%, with an in-hospital reinfarction 
rate of 3%. 
Baseline medical resources and costs. The median hospital 
length of stay was 8 days, and median coronary care unit stay 
was 3 days (Table 2). As noted previously, all patients had an 
acute cardiac catheterization, and 17% required at least one 
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Table I. Baseline Characteristics and Hospital Outcomes From the 
Primary. Angioplasty Registry' 
Baseline demographic, clinical and angiographic data 
Age (yr) 59 (5(/, 1~8) 
Range 24-90 
Male gender 74~ 
Anterior MI 42c.~ 
Initial Killip class >1 2~ 
No. of diseased vessels 
0 1 46ci 
2 34c~ 
3 2()c~ 
Time from symptom onset to 1st angiogram (h) 3.2 (2.4, 4.3) 
Initial TIMI flow grade 0 1 77% 
Infarct-related artery PTCA 9(V/ 
Ejection fraction (gi) 49 (41, 5;~) 
Hospital outcome 
Hospital death 4c;; ~ 
Reinfarction 3ci 
Stroke 1 q 
Heart failure 20ci 
Recurrent ischcmia 10% 
Continuous variables are displayed as median (25th, 75th percentiles} or 
percent of patients. MI = myocardial infarction: PTCA = percutancous trans- 
luminal coronary angioplasty: TIMI Thrombolvsis in Myocardial Infarction. 
repeat angiogram. Ninety-five percent of the registry patients 
had a revascularization procedure: 85% had angioplasty only; 
4% had coronary bypass surgery only, and 6% had angioplasty 
followed by bypass urgery. Repeat angioplasty was required in 
5% of patients; and emergency or urgent bypass urgery was 
performed in 6%. 
The total baseline hospital cost for the primary angioplasty 
reperfusion strategy used in the present study averaged 
$13,113, with the cost for a typical patient (i.e., median) of 
$10,548 (Table 2). Corresponding total mean and median 
hospital charges were $24,461 and $19,268. The difference in 
hospital charges between the sites with the lowest and highest 
mean values was $12,512, and the difference between the sites 
with the lowest and highest hospital cost was $3,600. Further- 
more, the sites with the lowest and highest charges were not 
the same as the sites with the lowest and highest cost. Baseline 
physician fees (cardiologist and cardiac surgeon) averaged 
$5,694 with a median of $4,907 (Table 2). The distribution of 
hospital costs by cost center is shown in Table 3. The largest 
cost centers for this acute myocardial infarction cohort were 
the intensive care unit and cardiology/catheterization labora- 
tory, followed by medical/surgical supplies and non-intensive 
care unit hospital room. 
Follow-up medical resources and costs. Major medical 
care during the 6-month follow-up period is shown in Table 4. 
Approximately one-third of the baseline hospital survivors 
were readmitted to the hospital, mostly for cardiac reasons; 6% 
had more than one cardiac-related readmission. Twenty-one 
percent had a repeat coronary angiogram, 13% had repeat 
coronary angioplasty and 3c//~ had coronary bypass surgery. As 
expected in a postinfarction cohort, physician visits were 
Table 2. Major Baseline Hospital Resource Consumption and Costs 
Medical resource use 





No PTCA/CABG 5% 
PTCA only 85% 
CABG only 4% 
PTCA and CABG 6% 
> 1 Pq'CA 5% 
Emergency or urgent CABG 6% 
lntraaortic balloon pump 13% 
Femoral vascular repair 1% 
RBC transfusion 18% 
Baseline medical costs and length of stay 
Hospital costs 
Mean _+ SD $13,113 + 8,782 
Median $10,548 
Hospital charges 
Mean - SD $24,461 -+ 17,710 
Median $19,268 
Physician fees 
Mean _- SD $5,694 _+ 2,559 
Median $4,907 
Total hospital LOS 8 (6, 10) 
Cardiac care unit LOS 3 (3, 5) 
Continuous variables arc displayed as median (25th, 75th percentiles) or 
percent of patients, unless otherwise specified. CABG = coronary artery bypass 
graft surgery: LOS = length of stay; PTCA = percutaneous transluminal 
corona U angioplasty; RBC - red blood cell. 
common during the first 6 months of follow-up. Visits to a 
specialist were more common than to primary care physicians. 
Mean follow-up hospital costs (including outpatient catheter- 
ization) were $3,174, mean hospital charges were $5,580, and 
mean physician fees (including inpatient care and outpatient 
visits) were $1,443. 
Predictors and correlates of baseline hospital costs. To 
identify the major predictors and correlates of baseline hospi- 
tal costs in primary angioplasty-treated patients, we con- 
structed a three-stage linear regression model. In the first stage 
Table 3. Baseline Hospital Cost Distribution by Cost Center 
Percent of 
Hospital Cost Center Total Cost Mean Cost 
Cath lab/cardioh)gy 19 $2,442 
ICU/CCU 20 $2,685 
Medical/surgical supplies 15 $1,973 
Non-ICU hospital room 12 $1,517 
l.aboralory 6 $844 
Pharmacy 6 $791 
OR/anesthesia 8 $1,101 
Miscellaneous 13 $1,759 
Total average cost $13,113 
CCU (ICU) = coronary (intensive) care unit: Cath lab = catheterization 
laborato~: OR = operating room. 
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Table 4. Major Follow-Up Medical Care and Costs* 
Medical resource use 
Follow-up hospital admissions 
Any 35% 
Cardiac related 29% 
Follow-up rocedures 
Cardiac atheterization 21% 
PTCA 13% 
CABG 3% 
Outpatient medical visits (->1) 
Cardiologist 87% 
Internist 34% 
Family or general practitioner 26% 
Any of these 95% 
Heart surgeon 10% 
Emergency room 15% 
Cardiac rehabilitation 14% 
Mean (-+SD) no. of outpatient medical 1.3 _+ 1.8 
visits in previous 6wkt 
Median (25th, 75th percentile) I (0, 2) 
Follow-up medical costs$ 
Hospital costs 
Mean +_ SD $3,174 + 6,539 
Median $0 
Hospital charges 
Mean _+ SD $5,580 _+ $11,383 
Median $0 
Physician fees (hospital + outpatient) 
Mean _+ SD $1,443 _+ 2,504 
Median $276 
*Figures refer to baseline hospital survivors. ?Assessed at6-month follow-up 
contact. :~Includes outpatient cardiac catheterization. Abbreviations as in 
Table 2. 
(predictive model), we tested the relation between baseline 
(i.e., pretreatment) demographic, clinical and angiographic 
factors and total baseline hospital costs. As shown in Table 5, 
the independent predictors of higher costs were older age, 
anterior myocardial infarction, higher initial Killip class and 
greater number of diseased vessels (Fig. 1 to 4). Each 10-year 
increase in age was associated with an increase in hospital costs 
Table 5. Multivariable Linear Regression Analysis of Baseline 
Hospital Costs 
Adjusted 
Dependent Variable Coefficient p Value 
Demographic, clinical and angiographic 
predictors* 
Age 0.0051 
Anterior MI location 0.1276 
Killip class (initial) 0.2806 
No. of diseased vessels 0.1222 





Procedural nd complication correlates+ 
Revascularization 0.4432 < 0.0001 
Recurrent ischemia 0.4275 < 0.0001 
New CHF or pulmonary edema 0.3853 < 0.0001 
Adjusted R2 - 0.420 
*Gender, initial Thrombolysis n Myocardial Infarction flow grade and 
ejection fraction not significant, Revascularization coded 1 ~ none; 2 = 
coronary angioplasty; 3 = bypass urgery only; 4 - both. Death, restenosis 
and reinfarction ot significant. CHF = congestive heart failure; Dependent 
Variable = log (hospital costs); MI = myocardial infarction. 
of 5%, adjusted for the other factors in the model (p = 0.049). 
Anterior infarction was associated with an adjusted increase in 
average hospital costs of 14% relative to inferior infarction 
(p = 0.03). Patients in Killip class I had a mean hospital cost of 
$11,267, whereas those in class II had an adjusted increase in 
costs of 32% (p < 0.0001). Extent of coronary disease was also 
an independent predictor of hospital costs (Fig. 4): Patients 
with zero- or one-vessel disease had a mean cost of $11,555; 
those with two-vessel disease had a 13% increase; and those 
with three-vessel disease a 28% increase in adjusted costs. 
Gender, initial Yhrombolysis in Myocardial Infarction (TIMI) 
flow grade and ejection fraction were not independent predic- 
tors of baseline costs. 
In the second stage (correlative or posttreatment model), 
we tested variables describing hospital procedures and adverse 
clinical outcomes (Table 4). The pattern of revascularization 
was a strong correlate of cost outcomes (Fig. 5): the need for 
Figure 1. Distribution of total baseline hospital 
costs for three age subgroups shown using Kaplan- ._o 
Meier curves. Y-axis indicates proportion of pa- ~. 
tients at or below a given cost; the 0.5-level indi- 
cates the median cost. X-axis indicates total 
hospital costs in increments of $10,000. The area 
above and to the left of each curve equals the 
average cost (~) for the group. Older age was 
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Figure 2. Distribution of total baseline hospital 
costs for anterior versus inferior myocardial in- 
farction (MI). Patients with an anterior infarction 
had consistently higher costs. Orientation as in 
Figure 1. 
Baseline Hospital Costs ($) 
bypass surgery instead of (adjusted mean cost increased by 
56%) or in addition to angioplasty (adjusted mean cost in- 
creased by 142%) substantially raised cost over that of coro- 
nary angioplasty alone ($11,927). Among the myocardial in- 
farction complication variables, recurrent ischemia (adjusted 
mean cost increase of 53%) and new or worsened congestive 
heart failure (adjusted mean cost increase 47%) were the 
strongest correlates (Fig. 6 and 7, respectively). Hospital death 
was not an independent correlate of hospital costs. 
Finally, when the independent variables from the prctrcat- 
ment model were combined with the posttreatment variables 
(combined model), only age remained significant from the 
pretreatment model, but all the independent posttreatment 
variables remained significant. 
Discussion 
The present study describes the baseline and 6-month 
economic outcomes associated with a reperfusion strategy of 
primary corona~ angioplasb,. The data are derived from a 
prospective registry of 270 patients with acute myocardial 
infarction treated at six experienced centers between 1990 and 
1992. The goals of the Primary Angioplasty Registry were to 
collect data that would allow comparison of primary angio- 
plasty results with previously published outcomes of thrombo- 
lytic-based reperfusion strategies and to assist in planning a 
large-scale randomized comparison of these two strategies 
(10). Three recently published randomized trials of primary 
angioplasty versus intravenous thrombolytic therapy (1-3) 
performed in highly experienced centers have reported higher 
infarct-related artery patency rates, better left ventricular 
function, less bleeding, and less recurrent ischemia for primary 
angioplasty. These results and trends toward improved mor- 
tality notwithstanding (7), recent commentators have sug- 
gested (14) that a shift toward more use of primary angioplasty 
would be warranted only if larger randomized trials showed 
both improved clinical outcomes and favorable cost outcomes 
relative to thrombolytic therapy. The present study provides 
new data about he costs of primary coronary angioplasty and 
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Figure 4. Distribution oftotal baseline hospital 
costs by number of diseased vessels• More se- 
vere coronary disease was associated with 
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Comparison with previous cost studies of primary angio- 
plasty. Four previous studies of primary angioplasty have 
compared hospital charges with those of thrombolytic therapy 
(9). The recently reported Primary Angioplasty in Myocardial 
Infarction (PAMI) randomized trial (1) found an average 
hospital charge of $24,569 for primary angioplasty versus 
$28,235 for recombinant tissue-type plasminogen activator 
(rt-PA). The Mayo Clinic randomized trial (2) found (approx- 
imate) hospital costs of $16,811 for primary angioplasty and 
$21,400 for rt-PA. The primary angioplasty costs in the present 
study are substantially ower than these figures, reflecting at 
least in part the important distinction between costs and 
charges• Furthermore, the baseline costs in the present study 
are comparable to the corresponding figures reported for the 
conservative arm of TIMI II (15,16): average hospital costs of 
$14,942 and average physician fees of $3,217 (both inflated to 
1991 dollars). Thus, the medical costs of primary angioplasty in
the present study are in the same range as those previously 
reported for thrombolytic-based reperfusion strategies• The 
principal imitation of the present study is the absence of a 
concurrent control group treated with thrombolytic therapy. 
Thus, we cannot directly evaluate whether the patterns of 
medical resource use and associated costs are actually equiv- 
alent or whether one strategy is less expensive. 
Hospital charges versus hospital costs. Results from the 
present study illustrate some of the pitfalls of using hospital 
charges rather than hospital costs as a measure of medical care 
resource consumption• The average hospital charge for pri- 
mary coronary angioplasty varied by up to $12,512 among the 
six participating sites, and the variation in hospital cost was 
$3,600• The latter difference isattributable todifferent practice 
patterns among physicians and different input prices for hos- 
pitals in different geographic regions (such as the costs of 
nursing and catheterization laboratory personnel). The much 
larger difference in charges is attributable to these factors plus 
substantial cost shifting by each hospital to cover unreimbursed 
and underreimbursed expenses (9). The hazards of using 
charge data in lieu of cost data were pointed out in an early 
report by Finkler (8). More recently, Hlatky et al. (11) showed 
that hospital charges would substantially overestimate the true 
cost savings associated with shifting patients with coronary 
disease from bypass urgery to coronary angioplasty. Because 
Figure 5. Distribution of total baseline hospital 
costs by pattern of revascularization received. 
Need for bypass surgery (CABG) instead of or in 
addition to angioplasty (PTCA) substantially in-
creased costs. Orientation as in Figure 1. 
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Figure 6. Distribution oftotal baseline hospi- 
tal costs for patients with versus without re- 
current ischemia. Orientation as in Figure 1. 
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charges reflect neither the true economic ost to socie~ of a 
medical treatment nor the amount hat payors actually reim- 
burse hospitals for this care, the use of such figures in economic 
studies or health policy analyses should be discouraged. 
Predictors and correlates of prima~ angioplasty costs. 
The patterns of medical resource consumption and the corre- 
sponding costs associated with a primary angioplasty treatment 
strategy for acute myocardial infarction are more strongly 
influenced by major complications or the need for additional 
revascularization than by patient selection (Table 4). For 
example, a 10-year difference in age was associated with a 5~ 
increase in adjusted hospital costs, whereas recurrent ischemia 
was associated with a 53% average increase, and need for 
bypass surgery after angioplasty was associated with a 142% 
increase. Of course, use of the entry and exclusion criteria 
typical of thrombolytic therapy trials undoubtedly produced a
lower risk subset of the acute myocardial infarction cohort 
(17). Primary angioplasty ispotentially applicable to a broader 
section of the acute myocardial infarction population with 
many more high-risk patients. In such a population, patient 
selection factors may well be more strongly related to cost. 
Future clinical trials. One benefit of the current study is 
that it provides data that can be used to estimate sample size 
requirements for future trials of primary angioplasty versus 
alternative r perfusion strategies that include an economic end 
point. Results from PAMI (1) and the Mayo Clinic primary 
angioplasty (2) trials suggest that hospital costs or charges for 
this strategy may be up to $4,000 less than for an rt-PA-based 
thrombolytic strategy. If the difference isactually only $2,000 in 
favor of primary angioplasty, projections based on our baseline 
hospital cost data suggest hat to detect his difference with a 
power of 80% and an alpha of 0.05 would require a study with 
-500 patients/treatment group. A recently initiated trial 
(GUSTO II) is testing a strategy of primary angioplasty versus 
thrombolytic therapy in -1,200 patients. 
Generalizability. Importantly, the results of the Primary 
Angioplasty Registry reflect the capabilities of some of the 
most dedicated and experienced centers in the United States. 
If the strategy is to have wider applicability, future studies will 
need to demonstrate hat these results are generalizable. 
Conclusions. The hospital costs of primary coronary angio- 
plasty therapy for patients with acute myocardial infarction 
c -  
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Figure 7. Distribution oftotal baseline hos- 
pital costs for patients with versus without 
new congestive h art failure (CHF) or pul- 
monary edema. Orientation as in Figure 1. 
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eligible for thrombolysis were most strongly influenced by 
infarction- and procedure-related complications, and patient 
selection factors had only a modest effect. However, extension 
of the procedure to higher risk patients ineligible for throm- 
bolysis may increase the relative importance of patient selec- 
tion factors in determining total cost. 
The collection of high quality economic data for this study was made possible by 
the diligent efforts of the study coordinators at each of the six clinical sites: Jan 
Shaftel, RN, Atlanta, Georgia; Abby Samuel, RN, Denise Muncey, RN, Greens- 
boro, North Carolina; Cheryl Dreiling, RN, Kansas City, Missouri; Carol 
Simpkiss, RN, Nancy Granger, RN, Orlando, Florida; Michele Strzelecki, RN, 
Royal Oak, Michigan; Deborah Koester, RN, Springfield, Illinois. We are also 
indebted to the billing orifice personnel at each site who provided medical bills for 
this study. Data entry and quality control at the Duke Economics and Quality of 
Life Coordinating Center were expertly performed by Lura Larson. Finally, we 
are grateful for the administrative support provided by Ms. Lori Baysden. 
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